Matthew Harrison
Stock Analyst at Morgan Stanley
(0)
# 3324
Out of 5,270 analysts
884
Total ratings
44.07%
Success rate
0.30%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Biogen | Maintains: Equal-Weight | 192 157 | 141.77 | 10.74% | 47 | Feb 13, 2025 | |
Gilead Sciences | Maintains: Overweight | 113 123 | 116.08 | 5.96% | 33 | Feb 12, 2025 | |
Vertex Pharmaceutica... | Maintains: Equal-Weight | 450 459 | 483.3 | -5.03% | 34 | Feb 11, 2025 | |
Insmed | Maintains: Overweight | 85 90 | 76.19 | 18.13% | 16 | Feb 6, 2025 | |
Moderna | Maintains: Equal-Weight | 70 38 | 30.27 | 25.54% | 24 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 3 | 1.42 | 111.27% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1235 1184 | 685.26 | 72.78% | 49 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 4 6 | 0.86 | 597.67% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 2 7 | 2.92 | 135.62% | 9 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 6 | 2.48 | 141.94% | 9 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 165 200 | 101.19 | 97.65% | 34 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 8 11 | 15 | -26.67% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 38 8 | 1.92 | 316.67% | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 515 510 | 622.66 | -18.09% | 24 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 7 | 1.77 | 295.48% | 18 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 115 112 | 71.05 | 57.64% | 20 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 34 34 | 15.32 | 121.93% | 14 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 32 32 | 22.95 | 39.43% | 27 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 42 38 | n/a | n/a | 6 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 14 4 | n/a | n/a | 6 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 321 319 | n/a | n/a | 27 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 21 19 | 2.23 | 752.02% | 3 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 13 14 | 0.95 | 1373.68% | 4 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Equal-Weight | 229 229 | n/a | n/a | 23 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 85 | 32.95 | 157.97% | 10 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Underweight | 60 60 | 3.9 | 1438.46% | 30 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 21 | n/a | n/a | 7 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 46 | 35.98 | 27.85% | 1 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 61 63 | 15.12 | 316.67% | 11 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 12 13 | 2.19 | 493.61% | 4 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | 0.92 | 8.7% | 3 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 10 | 17.73 | -43.6% | 9 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 27 8 | 3.21 | 149.22% | 9 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 57 44 | 25.93 | 69.69% | 28 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 19 10 | n/a | n/a | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 13 | 2.44 | 432.79% | 3 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 4 | 0.66 | 506.06% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | 0.44 | 581.82% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 203 216 | 111.4 | 93.9% | 8 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 5 | 1.59 | 214.47% | 13 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 5 | 2.05 | 143.9% | 6 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 178 182 | 211.49 | -13.94% | 8 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 12 9 | 3.91 | 130.18% | 13 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 30 40 | 45.55 | -12.18% | 6 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 279 282 | 310.8 | -9.27% | 36 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 220 210 | 243.64 | -13.81% | 7 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 736 621 | 10.1 | 6048.51% | 7 | Sep 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 6 3 | n/a | n/a | 5 | May 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 55 52 | 26.18 | 98.62% | 5 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 175 173 | 167.03 | 3.57% | 3 | Apr 6, 2022 |